Article info
PDFClinical and epidemiological research
Extended report
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- Correspondence to Maxime Dougados, Department of Rheumatology, Paris-Descartes University, Assistance Publique Hôpitaux de Paris, Cochin Hospital, 27 rue du Faubourg Saint-Jacques, Paris 75014, France; maxime.dougados{at}cch.aphp.fr
Citation
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Publication history
- Received June 21, 2016
- Revised September 6, 2016
- Accepted September 8, 2016
- First published September 29, 2016.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Lay summary
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/